It is also noteworthy that activators of PRDX4 could offer therapeutic potential for ameliorating the severity of NAFLD and intestinal dysfunction by suppressing oxidative damage. The gene discussed is PRDX4; the disease is metabolic dysfunction-associated steatotic liver disease.